ATE176400T1 - Therapeutische verwendungen von melanin - Google Patents
Therapeutische verwendungen von melaninInfo
- Publication number
- ATE176400T1 ATE176400T1 AT92902038T AT92902038T ATE176400T1 AT E176400 T1 ATE176400 T1 AT E176400T1 AT 92902038 T AT92902038 T AT 92902038T AT 92902038 T AT92902038 T AT 92902038T AT E176400 T1 ATE176400 T1 AT E176400T1
- Authority
- AT
- Austria
- Prior art keywords
- melanin
- active substance
- disease
- toxin
- mammal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
- C12Y114/18001—Tyrosinase (1.14.18.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/609,311 US5210076A (en) | 1988-09-13 | 1990-11-05 | Methods of treating Parkinson's disease using melanin |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE176400T1 true ATE176400T1 (de) | 1999-02-15 |
Family
ID=24440247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92902038T ATE176400T1 (de) | 1990-11-05 | 1991-11-05 | Therapeutische verwendungen von melanin |
Country Status (9)
Country | Link |
---|---|
US (4) | US5210076A (de) |
EP (1) | EP0510186B1 (de) |
JP (3) | JPH05503308A (de) |
AT (1) | ATE176400T1 (de) |
AU (1) | AU9028891A (de) |
CA (1) | CA2073180C (de) |
DE (1) | DE69130859T2 (de) |
ES (1) | ES2131525T3 (de) |
WO (1) | WO1992007580A1 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874091A (en) * | 1990-09-27 | 1999-02-23 | L'oreal | Cosmetic composition comprising a dispersion of lipid vesicles as well as melanin pigments |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US7556825B2 (en) * | 1993-04-02 | 2009-07-07 | Anticancer, Inc. | Method for promoting hair growth |
ATE209887T1 (de) | 1993-04-02 | 2001-12-15 | Anticancer Inc | Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel |
US5643554A (en) * | 1993-04-30 | 1997-07-01 | Dusa Pharmaceuticals, Inc. | Lipomelanim composition |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5824692A (en) * | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
US5849708A (en) * | 1995-06-06 | 1998-12-15 | Joslin Diabetes Center, Inc. | Promotion of eating behavior |
BR9708815B1 (pt) | 1996-04-23 | 2009-01-13 | compostos úteis para prevenção e tratamento de desordens do sistema nervoso central. | |
US6623724B2 (en) * | 1996-09-18 | 2003-09-23 | Applied Genetics Incorporated Dermatics | Dermatological compositions and methods |
US6214888B1 (en) * | 1996-09-18 | 2001-04-10 | Applied Genetics Incorporated | Dermatological compounds |
US6242415B1 (en) * | 1997-02-12 | 2001-06-05 | Sri International | Mediation of cytokines by melanin |
US5817048A (en) * | 1997-03-20 | 1998-10-06 | Brown University Research Foundation | Ultrasonic alternative to laser-based photodynamic therapy |
US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
DE19718826A1 (de) * | 1997-05-05 | 1998-11-12 | Marion S Dr Eckmiller | Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung |
US7214686B2 (en) * | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
US5980914A (en) * | 1997-08-22 | 1999-11-09 | P.N. Gerolymatos S.A. | Clioquinol for the treatment of Parkinson's disease |
AU4215499A (en) * | 1998-05-28 | 2002-07-08 | Codon Pharmaceuticals, Inc. | Treatment of neurodegenerative diseases |
US6506378B1 (en) | 1998-12-16 | 2003-01-14 | Arch Development Corporation | Vesicular monoamine transporter gene therapy in Parkinson's disease |
WO2001003649A2 (en) | 1999-07-13 | 2001-01-18 | Alpha Research Group, Llc | Compositions and methods for the treatment of parkinson's disease |
US20040229908A1 (en) * | 1999-07-13 | 2004-11-18 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias |
CN1436074A (zh) * | 2000-04-11 | 2003-08-13 | 宝生物工程株式会社 | 治疗剂 |
US6855925B2 (en) * | 2001-02-14 | 2005-02-15 | Picoliter Inc. | Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis |
DE10206723A1 (de) * | 2002-02-18 | 2003-09-04 | Ulrich Schraermeyer | Therapie von Erkrankungen des Auges und des Zentralen Nervensystems |
US6942663B2 (en) * | 2002-03-12 | 2005-09-13 | Board Of Regents, The University Of Texas System | Laser treatment of cutaneous vascular lesions |
CA2501348A1 (en) * | 2002-10-08 | 2004-04-22 | Allergan, Inc. | Treatment of dementia and parkinson's disease |
JP4724421B2 (ja) * | 2002-10-08 | 2011-07-13 | アラーガン、インコーポレイテッド | 神経変性を処置するためのα2Bまたは2B/2Cアドレナリン受容体アゴニスト |
WO2004076675A2 (en) | 2003-02-26 | 2004-09-10 | Johns Hopkins University | Glutamate transport modulatory compounds and methods |
US20040242729A1 (en) * | 2003-05-30 | 2004-12-02 | 3M Innovative Properties Company | Stabilized particle dispersions containing surface-modified inorganic nanoparticles |
US7256002B2 (en) * | 2003-08-12 | 2007-08-14 | The Institute For Ethnomedicine | Screening for neurotoxic amino acid associated with neurological disorders |
AU2004282201A1 (en) * | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
US7790226B2 (en) * | 2003-10-27 | 2010-09-07 | California Institute Of Technology | Pyrolyzed thin film carbon |
WO2005070005A2 (en) * | 2004-01-23 | 2005-08-04 | California Institute Of Technology | Pyrolyzed thin film carbon |
EP1778260A4 (de) * | 2004-07-30 | 2012-04-25 | Univ Mississippi | Potente immunstimulatorische extrakte aus mikroalgen |
JP2006076946A (ja) * | 2004-09-10 | 2006-03-23 | Hoyu Co Ltd | 重金属及び/又は放射性物質の排泄、又は除去を用途とするメラニン類含有組成物、及びメラニン類の用途 |
JP4578221B2 (ja) * | 2004-12-08 | 2010-11-10 | 月桂冠株式会社 | メラニン前駆体の製造方法 |
WO2009082735A1 (en) * | 2007-12-21 | 2009-07-02 | University Of Chicago | Melanins synthesized chemically or via enzyme catalysis |
JP2010115213A (ja) * | 2010-03-02 | 2010-05-27 | Gekkeikan Sake Co Ltd | メラニン前駆体の製造方法 |
CA2867832C (en) | 2011-03-18 | 2018-02-13 | Albert Einstein College Of Medicine Of Yeshiva University | Oral administration of melanin for protection against radiation |
US8610970B1 (en) * | 2011-08-20 | 2013-12-17 | Darwin Hu | Liquid crystal display (LCD) scanners |
ES2855076T3 (es) * | 2014-09-09 | 2021-09-23 | Herrera Arturo Solis | Métodos para tratar y prevenir enfermedades, trastornos y afecciones oculares con melanina |
KR101749675B1 (ko) * | 2015-07-20 | 2017-06-26 | 동국대학교 산학협력단 | 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물 |
WO2017065541A1 (ko) * | 2015-10-15 | 2017-04-20 | 동국대학교 산학협력단 | 퇴행성 뇌질환의 예방 또는 치료용 조성물 |
EP3173098A1 (de) * | 2015-11-27 | 2017-05-31 | Assistance Publique-Hopitaux De Paris | Immunstimulierende zusammensetzungen |
WO2017192501A1 (en) * | 2016-05-02 | 2017-11-09 | Goodwin & Wells LLC | Melanin compositions and devices for protecting tissues from radiation damage |
US11298379B2 (en) | 2020-04-16 | 2022-04-12 | James F. Kane | Compositions comprising milk fat globules and methods of making same |
KR102515986B1 (ko) * | 2020-07-29 | 2023-03-29 | 경희대학교 산학협력단 | 멜라닌 유사체 나노파티클을 포함하는 단백질 응집 저해용 약학 조성물 |
CN116832066B (zh) * | 2023-08-08 | 2024-01-12 | 青岛海洋生物医药研究院股份有限公司 | 乌贼墨提取物在制备抗多动症和抗抑郁症药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53124636A (en) * | 1977-04-04 | 1978-10-31 | Kisaku Mori | Method of increasing meranine contained in animal and plant |
JP2810953B2 (ja) * | 1988-09-13 | 1998-10-15 | バイオソース テクノロジーズ インコーポレイティド | タラニンを用いた神経系の病気の予防および治療のための医薬組成物 |
EP0363792B1 (de) * | 1988-10-03 | 1995-01-18 | Biosource Genetics Corporation | Herstellung von Melanin |
CA2086417C (en) * | 1990-06-29 | 1999-07-06 | Biosource Technologies, Inc. | Melanin production by transformed organisms |
-
1990
- 1990-11-05 US US07/609,311 patent/US5210076A/en not_active Expired - Fee Related
-
1991
- 1991-11-05 AU AU90288/91A patent/AU9028891A/en not_active Abandoned
- 1991-11-05 CA CA002073180A patent/CA2073180C/en not_active Expired - Fee Related
- 1991-11-05 ES ES92902038T patent/ES2131525T3/es not_active Expired - Lifetime
- 1991-11-05 DE DE69130859T patent/DE69130859T2/de not_active Expired - Fee Related
- 1991-11-05 WO PCT/US1991/008213 patent/WO1992007580A1/en active IP Right Grant
- 1991-11-05 EP EP92902038A patent/EP0510186B1/de not_active Expired - Lifetime
- 1991-11-05 JP JP4500929A patent/JPH05503308A/ja not_active Withdrawn
- 1991-11-05 AT AT92902038T patent/ATE176400T1/de not_active IP Right Cessation
-
1992
- 1992-12-10 US US07/988,739 patent/US5703051A/en not_active Expired - Fee Related
-
1995
- 1995-06-06 US US08/471,071 patent/US5817631A/en not_active Expired - Fee Related
- 1995-06-07 US US08/488,419 patent/US5776968A/en not_active Expired - Fee Related
-
2001
- 2001-06-25 JP JP2001191919A patent/JP2002058498A/ja active Pending
- 2001-06-25 JP JP2001191927A patent/JP2002037743A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69130859T2 (de) | 2000-01-27 |
US5703051A (en) | 1997-12-30 |
JPH05503308A (ja) | 1993-06-03 |
EP0510186A4 (en) | 1993-03-24 |
EP0510186B1 (de) | 1999-02-03 |
WO1992007580A1 (en) | 1992-05-14 |
AU9028891A (en) | 1992-05-26 |
ES2131525T3 (es) | 1999-08-01 |
US5776968A (en) | 1998-07-07 |
CA2073180A1 (en) | 1992-05-06 |
JP2002058498A (ja) | 2002-02-26 |
US5210076A (en) | 1993-05-11 |
EP0510186A1 (de) | 1992-10-28 |
JP2002037743A (ja) | 2002-02-06 |
CA2073180C (en) | 1998-12-08 |
DE69130859D1 (de) | 1999-03-18 |
US5817631A (en) | 1998-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE176400T1 (de) | Therapeutische verwendungen von melanin | |
DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
BG106058A (en) | Modulation of excitable tissue function by peripherally administered erythropoietin | |
BR9714677A (pt) | "enantiÈmeros 3-piridila e seu uso como analgésicos" | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
ATE361093T1 (de) | Selektiv auf die leber wirkende pharmazeutisch aktive substanz | |
FI935847A0 (fi) | L-DOPA-esterkompositioner | |
DE69815122D1 (de) | Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen | |
NL970006I2 (nl) | Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson. | |
DE69840909D1 (de) | Analoge von kokain | |
BR0108175A (pt) | Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais | |
ATE198550T1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
ATE155038T1 (de) | Zusammensetzung zur behandlung von degenerativen krankheiten des nervensystems | |
YU6196A (sh) | Transdermalna flasterska formulacija | |
WO2002100836A8 (en) | Compounds, compositions and methods for modulating beta-amyloid production | |
PT986393E (pt) | Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro | |
ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
Verghese et al. | A blind controlled trial of adrenocorticotropin and cerebral gangliosides in nerve regeneration in the rat | |
DE69307702T2 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
EA199800941A1 (ru) | Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона | |
NO961180L (no) | Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom | |
JP3167714B2 (ja) | 神経細胞保護剤 | |
PT97878A (pt) | Processo para a preparacao de uma composicao farmaceutica para uso oftalmico contendo hexetidina ou seus derivados ou sais |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |